|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SEC61G |
Gene summary for SEC61G |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SEC61G | Gene ID | 23480 |
| Gene name | SEC61 translocon subunit gamma | |
| Gene Alias | SSS1 | |
| Cytomap | 7p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006605 | UniProtAcc | A0A024QYZ0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23480 | SEC61G | GSM4909280 | Human | Breast | Precancer | 3.78e-02 | -4.57e-01 | 0.0305 |
| 23480 | SEC61G | GSM4909281 | Human | Breast | IDC | 8.61e-42 | 6.43e-01 | 0.21 |
| 23480 | SEC61G | GSM4909282 | Human | Breast | IDC | 6.91e-33 | 5.75e-01 | -0.0288 |
| 23480 | SEC61G | GSM4909285 | Human | Breast | IDC | 1.80e-26 | 5.67e-01 | 0.21 |
| 23480 | SEC61G | GSM4909287 | Human | Breast | IDC | 4.74e-67 | 7.05e-01 | 0.2057 |
| 23480 | SEC61G | GSM4909288 | Human | Breast | IDC | 2.58e-10 | 1.83e-01 | 0.0988 |
| 23480 | SEC61G | GSM4909290 | Human | Breast | IDC | 9.12e-72 | 8.87e-01 | 0.2096 |
| 23480 | SEC61G | GSM4909291 | Human | Breast | IDC | 7.08e-19 | 5.25e-01 | 0.1753 |
| 23480 | SEC61G | GSM4909294 | Human | Breast | IDC | 1.79e-25 | 3.05e-01 | 0.2022 |
| 23480 | SEC61G | GSM4909296 | Human | Breast | IDC | 3.03e-37 | 4.62e-01 | 0.1524 |
| 23480 | SEC61G | GSM4909297 | Human | Breast | IDC | 8.86e-32 | 1.36e-01 | 0.1517 |
| 23480 | SEC61G | GSM4909299 | Human | Breast | IDC | 1.51e-03 | 2.59e-01 | 0.035 |
| 23480 | SEC61G | GSM4909301 | Human | Breast | IDC | 6.07e-17 | 3.85e-01 | 0.1577 |
| 23480 | SEC61G | GSM4909302 | Human | Breast | IDC | 2.20e-02 | 3.79e-02 | 0.1545 |
| 23480 | SEC61G | GSM4909304 | Human | Breast | IDC | 3.46e-54 | 6.85e-01 | 0.1636 |
| 23480 | SEC61G | GSM4909306 | Human | Breast | IDC | 7.88e-12 | 3.90e-01 | 0.1564 |
| 23480 | SEC61G | GSM4909307 | Human | Breast | IDC | 1.19e-02 | 2.22e-01 | 0.1569 |
| 23480 | SEC61G | GSM4909309 | Human | Breast | IDC | 1.56e-08 | 1.93e-01 | 0.0483 |
| 23480 | SEC61G | GSM4909311 | Human | Breast | IDC | 4.85e-53 | -3.82e-01 | 0.1534 |
| 23480 | SEC61G | GSM4909312 | Human | Breast | IDC | 1.55e-20 | 6.71e-02 | 0.1552 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007180615 | Oral cavity | LP | protein transmembrane transport | 36/4623 | 59/18723 | 3.37e-09 | 1.44e-07 | 36 |
| GO:007097217 | Oral cavity | LP | protein localization to endoplasmic reticulum | 41/4623 | 74/18723 | 1.52e-08 | 5.63e-07 | 41 |
| GO:006500213 | Oral cavity | LP | intracellular protein transmembrane transport | 31/4623 | 51/18723 | 4.70e-08 | 1.64e-06 | 31 |
| GO:000661211 | Oral cavity | LP | protein targeting to membrane | 60/4623 | 131/18723 | 1.10e-07 | 3.59e-06 | 60 |
| GO:004504714 | Oral cavity | LP | protein targeting to ER | 25/4623 | 42/18723 | 1.64e-06 | 3.85e-05 | 25 |
| GO:007259914 | Oral cavity | LP | establishment of protein localization to endoplasmic reticulum | 26/4623 | 46/18723 | 3.95e-06 | 8.19e-05 | 26 |
| GO:000662017 | Oral cavity | LP | posttranslational protein targeting to endoplasmic reticulum membrane | 9/4623 | 12/18723 | 3.52e-04 | 3.49e-03 | 9 |
| GO:007259416 | Prostate | BPH | establishment of protein localization to organelle | 142/3107 | 422/18723 | 4.01e-18 | 1.31e-15 | 142 |
| GO:000660518 | Prostate | BPH | protein targeting | 102/3107 | 314/18723 | 2.51e-12 | 2.05e-10 | 102 |
| GO:00709728 | Prostate | BPH | protein localization to endoplasmic reticulum | 36/3107 | 74/18723 | 1.61e-10 | 9.22e-09 | 36 |
| GO:009015016 | Prostate | BPH | establishment of protein localization to membrane | 77/3107 | 260/18723 | 1.06e-07 | 2.56e-06 | 77 |
| GO:00725997 | Prostate | BPH | establishment of protein localization to endoplasmic reticulum | 23/3107 | 46/18723 | 1.71e-07 | 3.85e-06 | 23 |
| GO:00450476 | Prostate | BPH | protein targeting to ER | 21/3107 | 42/18723 | 5.88e-07 | 1.15e-05 | 21 |
| GO:000662014 | Prostate | BPH | posttranslational protein targeting to endoplasmic reticulum membrane | 7/3107 | 12/18723 | 1.25e-03 | 7.57e-03 | 7 |
| GO:00718067 | Prostate | BPH | protein transmembrane transport | 19/3107 | 59/18723 | 2.37e-03 | 1.29e-02 | 19 |
| GO:00650024 | Prostate | BPH | intracellular protein transmembrane transport | 16/3107 | 51/18723 | 6.72e-03 | 3.02e-02 | 16 |
| GO:007259417 | Prostate | Tumor | establishment of protein localization to organelle | 151/3246 | 422/18723 | 3.19e-20 | 2.83e-17 | 151 |
| GO:000660519 | Prostate | Tumor | protein targeting | 109/3246 | 314/18723 | 6.11e-14 | 7.30e-12 | 109 |
| GO:007097216 | Prostate | Tumor | protein localization to endoplasmic reticulum | 36/3246 | 74/18723 | 5.66e-10 | 2.95e-08 | 36 |
| GO:007259913 | Prostate | Tumor | establishment of protein localization to endoplasmic reticulum | 23/3246 | 46/18723 | 3.87e-07 | 8.56e-06 | 23 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414118 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
| hsa0414518 | Breast | Precancer | Phagosome | 27/684 | 152/8465 | 7.37e-05 | 6.85e-04 | 5.25e-04 | 27 |
| hsa0414119 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
| hsa0414519 | Breast | Precancer | Phagosome | 27/684 | 152/8465 | 7.37e-05 | 6.85e-04 | 5.25e-04 | 27 |
| hsa0511022 | Breast | IDC | Vibrio cholerae infection | 17/867 | 50/8465 | 4.82e-06 | 6.82e-05 | 5.10e-05 | 17 |
| hsa0414522 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
| hsa0414124 | Breast | IDC | Protein processing in endoplasmic reticulum | 36/867 | 174/8465 | 2.73e-05 | 2.86e-04 | 2.14e-04 | 36 |
| hsa0511032 | Breast | IDC | Vibrio cholerae infection | 17/867 | 50/8465 | 4.82e-06 | 6.82e-05 | 5.10e-05 | 17 |
| hsa0414532 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
| hsa0414134 | Breast | IDC | Protein processing in endoplasmic reticulum | 36/867 | 174/8465 | 2.73e-05 | 2.86e-04 | 2.14e-04 | 36 |
| hsa0414541 | Breast | DCIS | Phagosome | 35/846 | 152/8465 | 1.67e-06 | 2.45e-05 | 1.81e-05 | 35 |
| hsa0511041 | Breast | DCIS | Vibrio cholerae infection | 17/846 | 50/8465 | 3.45e-06 | 4.45e-05 | 3.28e-05 | 17 |
| hsa0414143 | Breast | DCIS | Protein processing in endoplasmic reticulum | 36/846 | 174/8465 | 1.60e-05 | 1.91e-04 | 1.41e-04 | 36 |
| hsa0414551 | Breast | DCIS | Phagosome | 35/846 | 152/8465 | 1.67e-06 | 2.45e-05 | 1.81e-05 | 35 |
| hsa0511051 | Breast | DCIS | Vibrio cholerae infection | 17/846 | 50/8465 | 3.45e-06 | 4.45e-05 | 3.28e-05 | 17 |
| hsa0414153 | Breast | DCIS | Protein processing in endoplasmic reticulum | 36/846 | 174/8465 | 1.60e-05 | 1.91e-04 | 1.41e-04 | 36 |
| hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
| hsa0414520 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
| hsa0511016 | Cervix | CC | Vibrio cholerae infection | 18/1267 | 50/8465 | 1.91e-04 | 1.11e-03 | 6.55e-04 | 18 |
| hsa0306010 | Cervix | CC | Protein export | 10/1267 | 23/8465 | 9.64e-04 | 4.22e-03 | 2.49e-03 | 10 |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SEC61G | SNV | Missense_Mutation | c.121G>A | p.Ala41Thr | p.A41T | P60059 | protein_coding | tolerated(0.07) | benign(0.048) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SEC61G | insertion | Frame_Shift_Ins | novel | c.205_206insTTAATTTAGAAATA | p.Ter69PhefsTer16 | p.*69Ffs*16 | P60059 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SEC61G | SNV | Missense_Mutation | c.71N>A | p.Arg24Lys | p.R24K | P60059 | protein_coding | tolerated(0.36) | benign(0.024) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SEC61G | SNV | Missense_Mutation | c.191T>C | p.Ile64Thr | p.I64T | P60059 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SEC61G | SNV | Missense_Mutation | novel | c.105G>T | p.Lys35Asn | p.K35N | P60059 | protein_coding | tolerated(0.05) | possibly_damaging(0.862) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| SEC61G | SNV | Missense_Mutation | novel | c.197T>C | p.Val66Ala | p.V66A | P60059 | protein_coding | deleterious(0.01) | possibly_damaging(0.672) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SEC61G | deletion | Frame_Shift_Del | novel | c.70delN | p.Arg24AspfsTer19 | p.R24Dfs*19 | P60059 | protein_coding | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| SEC61G | SNV | Missense_Mutation | c.67N>G | p.Lys23Glu | p.K23E | P60059 | protein_coding | deleterious(0.05) | benign(0.094) | TCGA-49-4488-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SEC61G | SNV | Missense_Mutation | c.107N>A | p.Ile36Asn | p.I36N | P60059 | protein_coding | deleterious(0.03) | benign(0.19) | TCGA-86-A4JF-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | unknown | PD | |
| SEC61G | SNV | Missense_Mutation | c.173A>G | p.His58Arg | p.H58R | P60059 | protein_coding | tolerated(0.06) | probably_damaging(0.996) | TCGA-37-3789-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |